[HTML][HTML] ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

DW Lee, BD Santomasso, FL Locke, A Ghobadi… - Biology of blood and …, 2019 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most
promising therapies for hematologic malignancies. Two CAR T products were recently …

Mouse models of graft-versus-host disease: advances and limitations

MA Schroeder, JF DiPersio - Disease models & …, 2011 - journals.biologists.com
The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …

Cytokines and hematopoietic stem cell mobilization

B Nervi, DC Link, JF DiPersio - Journal of cellular biochemistry, 2006 - Wiley Online Library
Hematopoietic stem cell transplantation (HSCT) has become the standard of care for the
treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute …

[HTML][HTML] Recurring mutations found by sequencing an acute myeloid leukemia genome

ER Mardis, L Ding, DJ Dooling… - … England Journal of …, 2009 - Mass Medical Soc
Background The full complement of DNA mutations that are responsible for the
pathogenesis of acute myeloid leukemia (AML) is not yet known. Methods We used …

[HTML][HTML] DNMT3A Mutations in Acute Myeloid Leukemia

TJ Ley, L Ding, MJ Walter, MD McLellan… - … England Journal of …, 2010 - Mass Medical Soc
Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …

[HTML][HTML] Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

L Ding, TJ Ley, DE Larson, CA Miller, DC Koboldt… - Nature, 2012 - nature.com
Most patients with acute myeloid leukaemia (AML) die from progressive disease after
relapse, which is associated with clonal evolution at the cytogenetic level,. To determine the …

[HTML][HTML] The origin and evolution of mutations in acute myeloid leukemia

JS Welch, TJ Ley, DC Link, CA Miller, DE Larson… - Cell, 2012 - cell.com
Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …

[HTML][HTML] A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

S Verstovsek, RA Mesa, J Gotlib, RS Levy… - … England Journal of …, 2012 - Mass Medical Soc
Background Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically
significant activity in myelofibrosis. Methods In this double-blind trial, we randomly assigned …

Age-related mutations associated with clonal hematopoietic expansion and malignancies

M Xie, C Lu, J Wang, MD McLellan, KJ Johnson… - Nature medicine, 2014 - nature.com
Several genetic alterations characteristic of leukemia and lymphoma have been detected in
the blood of individuals without apparent hematological malignancies. The Cancer Genome …

[HTML][HTML] DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

TJ Ley, ER Mardis, L Ding, B Fulton, MD McLellan… - Nature, 2008 - nature.com
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed …